Development
Acrivon Therapeutics, Inc.
ACRV
$1.35
$0.108.00%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -3.97% | -9.08% | -42.86% | 2.92% | -58.04% |
| Total Depreciation and Amortization | 3.10% | 3.20% | 0.00% | 7.76% | 48.72% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.02% | 24.00% | 29.38% | 389.59% | -35.02% |
| Change in Net Operating Assets | -28.01% | 695.35% | 76.97% | -181.46% | 562.10% |
| Cash from Operations | -7.62% | 19.77% | -21.41% | -43.44% | -11.97% |
| Capital Expenditure | 100.00% | -348.00% | 90.04% | 41.08% | 60.34% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -92.21% | 107.98% | 109.86% | -112.14% | -- |
| Cash from Investing | -92.16% | 107.33% | 109.81% | -110.70% | -4,101.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -79.42% | -- | -- | 435,141.67% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -1,484.15% | -1,390.91% |
| Cash from Financing | -79.42% | -- | -- | 72,857.14% | -1,172.73% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -177.44% | 622.41% | 20.73% | 95.05% | -649.47% |